• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Chemother . Post COVID-19 condition of the Omicron variant of SARS-CoV-2

tetano

Editor, Senior Moderator
J Infect Chemother


. 2022 Aug 10;S1341-321X(22)00233-1.
doi: 10.1016/j.jiac.2022.08.007. Online ahead of print.
Post COVID-19 condition of the Omicron variant of SARS-CoV-2


S Morioka[SUP] 1 [/SUP], S Tsuzuki[SUP] 2 [/SUP], M Suzuki[SUP] 3 [/SUP], M Terada[SUP] 4 [/SUP], M Akashi[SUP] 3 [/SUP], Y Osanai[SUP] 3 [/SUP], C Kuge[SUP] 3 [/SUP], M Sanada[SUP] 3 [/SUP], K Tanaka[SUP] 3 [/SUP], T Maruki[SUP] 3 [/SUP], K Takahashi[SUP] 3 [/SUP], S Saito[SUP] 3 [/SUP], K Hayakawa[SUP] 5 [/SUP], K Teruya[SUP] 6 [/SUP], M Hojo[SUP] 7 [/SUP], N Ohmagari[SUP] 5 [/SUP]



Affiliations

Abstract

Objectives: To investigate the prevalence of post coronavirus disease (COVID-19) condition of the Omicron variant in comparison to other strains.
Study design: A single-center cross-sectional study.
Methods: Patients who recovered from Omicron COVID-19 infection (Omicron group) were interviewed via telephone, and patients infected with other strains (control group) were surveyed via a self-reporting questionnaire. Data on patients' characteristics, information regarding the acute-phase COVID-19, as well as presence and duration of COVID-19-related symptoms were obtained. Post COVID-19 condition in this study was defined as a symptom that lasted for at least 2 months, within 3 months of COVID-19 onset. We investigated and compared the prevalence of post COVID-19 condition in both groups after performing propensity score matching.
Results: We conducted interviews for 53 out of 128 patients with Omicron and obtained 502 responses in the control group. After matching cases with controls, 18 patients from both groups had improved covariate balance of the factors: older adult, female sex, obesity, and vaccination status. There were no significant differences in the prevalence of each post COVID-19 condition between the two groups. The number of patients with at least one post COVID-19 condition in the Omicron and control groups were 1 (5.6%) and 10 (55.6%) (p = 0.003), respectively.
Conclusions: The prevalence of post Omicron COVID-19 conditions was less than that of the other strains. Further research with a larger sample size is needed to investigate the precise epidemiology of post COVID-19 condition of Omicron, and its impact on health-related quality of life and social productivity.

Keywords: Long COVID; Omicron; Post COVID-19 conditions; WHO definition.
 
Back
Top Bottom